Myriad and AbbVie Genetics expand Tumor BRACAnalysis CDx collaboration Myriad Genetics.

The acquisition of Hi-Tech further diversifies our niche branded and generic product bottom and brings with it features that will assist us continue to develop and diversify our pipeline and revenue base in to the future.’ Financial Results for the Quarter Ended March 31, 2014 Consolidated revenue for the first one fourth of 2014 was $90.6 million, an increase of 23 percent over the first quarter 2013 consolidated revenue of $73.9 million. Consolidated gross margin for the initial one fourth of 2014 was 54.8 percent compared to 53.0 percent in the comparable prior year period. The increase in the Company's consolidated gross margin was also due to the newly acquired branded ophthalmic products which generate gross margins higher than the Company's historical average. Net gain for the first quarter of 2014 was $9.8 million, or $0.08 per diluted share, compared to net income of $10.8 million, or $0.10 per diluted share, in the prior year quarter.Major barriers to care exist among prison inmates also. In accordance to data from the Department of Corrections, 40 percent of the 6000 inmates in the brand new Mexico Division of Corrections are contaminated with HCV. As of 2003, not really a single individual in the correctional program experienced received treatment for HCV contamination. Lack of usage of specialty care services at community-based health centers is a problem, for uninsured patients particularly.18,19 Community-based health centers are the most culturally suitable and accessible selections for care often, in rural areas particularly, and providers at these centers can establish trust through ongoing interactions with patients.